Skip to main content

Table 3 Trials of bevacizumab in early-stage breast cancer: preoperative therapy

From: Antiangiogenic therapy for breast cancer

Reference Phase Number of patients Treatment Response rate (%)
Hurvitz et al. [30] II (randomised) 37 of 90 planned (HER2-negative) A: TAC + B (7.5 mg/kg) All regimens: RR 95; CR 59; PR 35
    B: TAC + placebo A: PR 58; CR 42
    C: TAC + B (15 mg/kg) B + D: PR 27; CR 64
    D: TAC + placebo (2:1:2:1, randomisation) D: PR 21; CR 71
Makhoul et al. [31] II 36 (11 HER2-negative) Bevacizumab + docetaxel + cyclophosphamide (4 cycles) → doxorubicin (4 cycles) → bevacizumab (adjuvant, 9 cycles) PR 31; CR 39; pCR breast 38; pCR breast + axilla 29
Greil et al. [32] II 18 (HER2-negative) Bevacizumab × 5* + (docetaxel + capecitabine) × 6* pCR 22
Balduzzi et al. [33] II 30 Epirubicin + cisplatin + fluorouracil × 4* → bevacizumab + paclitaxel × 3* pCR 33; CR + PR 87
Wedam et al. [34] II 21 (81% HER2-negative) Bevacizumab × 1* → bevacizumab + doxorubicin + docetaxel × 6* PR 67; CR 0
Lyons et al. [35] II 49 (number of patients receiving bevacizumab not reported) Docetaxel + bevacizumab or docetaxel CR 14; PR 65
Raefsky et al. [36] II 25 Nab-paclitaxel + carboplatin × 6* + trastuzumab + bevacizumab × 23* pCR 26; PR 16
Locatelli et al. [37] II (randomised) 23 (19 evaluable; locally advanced) B → vinorelbine + capecitabine (9 pts) NR
    B + vinorelbine + capecitabine (14 pts) NR
Torrisi et al. [38] II 37 (36 evaluable; estrogen and/or progesterone positive) Bevacizumab + capecitabine + vinorelbine + letrozole RR 86; pCR 0
  1. Studies with ≥15 evaluable patients are included. B, bevacizumab, in combination with chemotherapy preoperatively plus adjuvant for 52 weeks; CR, complete response; NR, not reported; pCR, pathological complete response; PR, partial response; pts, patients; RR, response rate; TAC, docetaxel, doxorubicin, cyclophosphamide (six cycles preoperatively). *Times of treatment.